Extended-release Painkiller Approved

Nucynta ER sanctioned for chronic pain in adults

FRIDAY, Aug. 26 (HealthDay News) -- Nucynta ER (tapentadol extended release) has been approved by the U.S. Food and Drug Administration to treat moderate-to-severe chronic pain in adults, maker Janssen Pharmaceuticals said.

The extended-release version of the opioid drug is taken twice daily. The original formulation of Nucynta was approved by the FDA in 2008.

Almost one-third of Americans will have chronic pain at some point in their lives, making it the most common form of long-term disability, the drug maker said.

In clinical testing of Nucynta, the most common side effects were nausea, constipation, headache and dizziness. People taking the drug must not consume alcohol or any medications that contain alcohol, Janssen said in a news release.

Janssen is a unit of Johnson & Johnson, New Brunswick, N.J.

More information

Medline Plus has more about this drug.

Scott Roberts

Related Articles

Learn More About Sharp
Sharp HealthCare is San Diego's health care leader with seven hospitals, two medical groups and a health plan. Learn more about our San Diego hospitals, choose a Sharp-affiliated San Diego doctor or browse our comprehensive medical services.

Health News is provided as a service to Sharp Web site users by HealthDay. Sharp HealthCare nor its employees, agents, or contractors, review, control, or take responsibility for the content of these articles. Please read the Terms of Use for more information.